Paris' Gecko Biomedical has raised $25 million in support of its drug delivering biopolymer platform for tissue reconstruction. Co-financed by MIT's Robert Langer, the company is aiming to earn its first approval within a year, for a cardiovascular reconstruction candidate. More from FierceMedicalDevices